{"id":917419,"date":"2025-12-08T10:48:30","date_gmt":"2025-12-08T15:48:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/deadline-approaching-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-class-action-by-december-15-2025\/"},"modified":"2025-12-08T10:48:30","modified_gmt":"2025-12-08T15:48:30","slug":"deadline-approaching-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-class-action-by-december-15-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/deadline-approaching-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-class-action-by-december-15-2025\/","title":{"rendered":"DEADLINE APPROACHING: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Inquire About a Securities Fraud Class Action by December 15, 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">PHILADELPHIA, Dec.  08, 2025  (GLOBE NEWSWIRE) &#8212; National plaintiffs\u2019 law firm\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rC3sdx-ukbzYpBmCrqK5fvHrD9UCch_GnO9aRf3gAhCcTWj65qdDM2PM-r86mcXcYZLMpKhlFZm4g2lxGya1AwC9UIJaVkmSNN_Pc7lkql0=\" rel=\"nofollow\" target=\"_blank\"><u>Berger Montague PC<\/u><\/a> announces a class action lawsuit against<strong> MoonLake Immunotherapeutics (NASDAQ: MLTX)<\/strong> (\u201cMoonLake\u201d or the \u201cCompany\u201d) on behalf of investors who purchased MoonLake shares during the period of\u00a0<strong>March 10, 2024 through September 29, 2025 <\/strong>(the \u201cClass Period\u201d).<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <em>Investor Deadline:<\/em><br \/>\n        <\/strong><br \/>\n        <em> Investors who purchased MoonLake<\/em><br \/>\n        <em>securities during the Class Period may, no later than <\/em><br \/>\n        <strong><br \/>\n          <em>December 15, 2025<\/em><br \/>\n        <\/strong><br \/>\n        <em>, seek to be appointed as a lead plaintiff representative of the class. To learn your rights,<\/em><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cAgNUlXKsxEbttYnl9O_lrxZZo1u6rpLXX97Y7u3F7krugQfWhZ0VTaNsjTUyP0EhvCBBiphAOy6dbTFXHyrGkeKYNyXZVEpJX_CQjUWCTaT1NRlSI3EmJRa5aQNV4ivEYLIigl_dZYmF6t6MBwnumgXQIYUs9yEEkrU65vmpt2jNv4d82TEvU984gHcFBDH\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong><br \/>\n            <u>CLICK HERE<\/u><br \/>\n          <\/strong><br \/>\n        <\/a>.<\/p>\n<p align=\"justify\">MoonLake is a clinical-stage biotechnology company headquartered in Zug, Switzerland.<\/p>\n<p align=\"justify\">According to the lawsuit,\u00a0MoonLake and certain executives made false and misleading statements regarding the Company\u2019s only drug candidate,\u00a0sonelokimab (SLK), in testing as a treatment for certain skin conditions. The complaint alleges that the Company repeatedly promoted SLK\u2019s Nanobody structure as providing superior clinical advantages over traditional monoclonal antibodies, such as FDA-approved BIMZELX.<\/p>\n<p align=\"justify\">On\u00a0September 28, 2025, the Company announced\u00a0Phase 3 clinical trial results for SLK, which, according to the lawsuit, showed\u00a0that SLK failed to achieve efficacy comparable to BIMZELX. Analysts reportedly described the data as a \u201cdisastrous result,\u201d and\u00a0MoonLake\u2019s stock declined nearly <strong><em>90%<\/em><\/strong>, or $55.75 per share, in a single trading session.<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <em>If you are a MoonLake investor and would like to learn more about this action, <\/em><br \/>\n        <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cAgNUlXKsxEbttYnl9O_lllgathT9gK_7OAFHmUoAXgS8j4OTARjG3HkMDRGvW6y9-vhQAQM0ihmjpZCnPB__ffKqmRdnsTQv94BfPf_NLCTN-0HmpFf3E2zPnvAgeKAOLkG2ZAfPDXFmM2ZYYTZBlTJotYGChp-2kzRvfjc1ilIdUe7j_rrU5PB0W8q0LOk\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong><br \/>\n            <em><br \/>\n              <u>CLICK HERE<\/u><br \/>\n            <\/em><br \/>\n          <\/strong><br \/>\n        <\/a><br \/>\n        <strong><br \/>\n          <em>or please contact Berger Montague: Andrew Abramowitz at <\/em><br \/>\n        <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PK9mWudjHLJ8Tgd6LBkHTADtvf5VtTi493Gg6UFXka61xE361XwlUo7HFKgh0EyIxQFwdFNq1JdgP3OtTrE1s26EDS_mESVpCEAJYmm7anlawm9Zk5xl5N7BVoKAAQho\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong><br \/>\n            <em><br \/>\n              <u>aabramowitz@bergermontague.com<\/u><br \/>\n            <\/em><br \/>\n          <\/strong><br \/>\n        <\/a><br \/>\n        <strong><br \/>\n          <em> or (215) 875-3015, or Caitlin Adorni at <\/em><br \/>\n        <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PVo5Pq_9h4SfyRoLvVyCHFp6fRlaLJmRGsUzRr4oqpCPVsEPF2c4cSu-vY4dLxtrJ_P2V5bmMy-WrU98Y8ny9_rqqkPQMF_iRcrt_yGXwKD_Pw46ldcJ69koqwiOEQn3\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong><br \/>\n            <em><br \/>\n              <u>cadorni@bergermontague.com<\/u><br \/>\n            <\/em><br \/>\n          <\/strong><br \/>\n        <\/a><br \/>\n        <strong><br \/>\n          <em> or (267)764-4865.<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p>\n        <strong>About Berger Montague<\/strong>\n      <\/p>\n<p align=\"justify\">Berger Montague is one of the nation\u2019s preeminent law firms focusing on complex civil litigation, class actions, and mass torts in federal and state courts throughout the United States. With more than $2.4 billion in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, environmental law, employment law, securities, and whistleblower cases, among many other practice areas. For over 55 years, Berger Montague has played leading roles in precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE.<\/p>\n<p align=\"justify\">\n        <strong>For more information or to discuss your rights, please contact:<\/strong><br \/>\n        <br \/>Andrew Abramowitz<br \/><em>Senior Counsel<\/em><br \/>Berger Montague<br \/>(215) 875-3015<br \/>aabramowitz@bergermontague.com<\/p>\n<p align=\"justify\">Caitlin Adorni<br \/><em>Director of Portfolio &amp; Institutional Client Monitoring Services<\/em><br \/>Berger Montague<br \/>(267) 764-4865<br \/>cadorni@bergermontague.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODU2OCM3MzExMTc3IzIwODI5NjI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZjJjZDkzZjctZjYyMC00OWE5LTg2ZWYtOWU3ZDdmMDE4Zjg5LTEwOTQ1MzMtMjAyNS0xMi0wOC1lbg==\/tiny\/Berger-Montague.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PHILADELPHIA, Dec. 08, 2025 (GLOBE NEWSWIRE) &#8212; National plaintiffs\u2019 law firm\u00a0Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) (\u201cMoonLake\u201d or the \u201cCompany\u201d) on behalf of investors who purchased MoonLake shares during the period of\u00a0March 10, 2024 through September 29, 2025 (the \u201cClass Period\u201d). Investor Deadline: Investors who purchased MoonLake securities during the Class Period may, no later than December 15, 2025 , seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE . MoonLake is a clinical-stage biotechnology company headquartered in Zug, Switzerland. According to the lawsuit,\u00a0MoonLake and certain executives made false and misleading statements regarding the Company\u2019s only drug candidate,\u00a0sonelokimab (SLK), in testing as a treatment &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/deadline-approaching-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-class-action-by-december-15-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;DEADLINE APPROACHING: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Inquire About a Securities Fraud Class Action by December 15, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-917419","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>DEADLINE APPROACHING: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Inquire About a Securities Fraud Class Action by December 15, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/deadline-approaching-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-class-action-by-december-15-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DEADLINE APPROACHING: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Inquire About a Securities Fraud Class Action by December 15, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PHILADELPHIA, Dec. 08, 2025 (GLOBE NEWSWIRE) &#8212; National plaintiffs\u2019 law firm\u00a0Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) (\u201cMoonLake\u201d or the \u201cCompany\u201d) on behalf of investors who purchased MoonLake shares during the period of\u00a0March 10, 2024 through September 29, 2025 (the \u201cClass Period\u201d). Investor Deadline: Investors who purchased MoonLake securities during the Class Period may, no later than December 15, 2025 , seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE . MoonLake is a clinical-stage biotechnology company headquartered in Zug, Switzerland. According to the lawsuit,\u00a0MoonLake and certain executives made false and misleading statements regarding the Company\u2019s only drug candidate,\u00a0sonelokimab (SLK), in testing as a treatment &hellip; Continue reading &quot;DEADLINE APPROACHING: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Inquire About a Securities Fraud Class Action by December 15, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/deadline-approaching-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-class-action-by-december-15-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-08T15:48:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODU2OCM3MzExMTc3IzIwODI5NjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/deadline-approaching-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-class-action-by-december-15-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/deadline-approaching-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-class-action-by-december-15-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"DEADLINE APPROACHING: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Inquire About a Securities Fraud Class Action by December 15, 2025\",\"datePublished\":\"2025-12-08T15:48:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/deadline-approaching-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-class-action-by-december-15-2025\\\/\"},\"wordCount\":410,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/deadline-approaching-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-class-action-by-december-15-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5ODU2OCM3MzExMTc3IzIwODI5NjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/deadline-approaching-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-class-action-by-december-15-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/deadline-approaching-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-class-action-by-december-15-2025\\\/\",\"name\":\"DEADLINE APPROACHING: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Inquire About a Securities Fraud Class Action by December 15, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/deadline-approaching-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-class-action-by-december-15-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/deadline-approaching-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-class-action-by-december-15-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5ODU2OCM3MzExMTc3IzIwODI5NjI=\",\"datePublished\":\"2025-12-08T15:48:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/deadline-approaching-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-class-action-by-december-15-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/deadline-approaching-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-class-action-by-december-15-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/deadline-approaching-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-class-action-by-december-15-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5ODU2OCM3MzExMTc3IzIwODI5NjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5ODU2OCM3MzExMTc3IzIwODI5NjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/deadline-approaching-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-class-action-by-december-15-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"DEADLINE APPROACHING: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Inquire About a Securities Fraud Class Action by December 15, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DEADLINE APPROACHING: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Inquire About a Securities Fraud Class Action by December 15, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/deadline-approaching-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-class-action-by-december-15-2025\/","og_locale":"en_US","og_type":"article","og_title":"DEADLINE APPROACHING: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Inquire About a Securities Fraud Class Action by December 15, 2025 - Market Newsdesk","og_description":"PHILADELPHIA, Dec. 08, 2025 (GLOBE NEWSWIRE) &#8212; National plaintiffs\u2019 law firm\u00a0Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) (\u201cMoonLake\u201d or the \u201cCompany\u201d) on behalf of investors who purchased MoonLake shares during the period of\u00a0March 10, 2024 through September 29, 2025 (the \u201cClass Period\u201d). Investor Deadline: Investors who purchased MoonLake securities during the Class Period may, no later than December 15, 2025 , seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE . MoonLake is a clinical-stage biotechnology company headquartered in Zug, Switzerland. According to the lawsuit,\u00a0MoonLake and certain executives made false and misleading statements regarding the Company\u2019s only drug candidate,\u00a0sonelokimab (SLK), in testing as a treatment &hellip; Continue reading \"DEADLINE APPROACHING: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Inquire About a Securities Fraud Class Action by December 15, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/deadline-approaching-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-class-action-by-december-15-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-08T15:48:30+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODU2OCM3MzExMTc3IzIwODI5NjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/deadline-approaching-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-class-action-by-december-15-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/deadline-approaching-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-class-action-by-december-15-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"DEADLINE APPROACHING: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Inquire About a Securities Fraud Class Action by December 15, 2025","datePublished":"2025-12-08T15:48:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/deadline-approaching-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-class-action-by-december-15-2025\/"},"wordCount":410,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/deadline-approaching-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-class-action-by-december-15-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODU2OCM3MzExMTc3IzIwODI5NjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/deadline-approaching-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-class-action-by-december-15-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/deadline-approaching-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-class-action-by-december-15-2025\/","name":"DEADLINE APPROACHING: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Inquire About a Securities Fraud Class Action by December 15, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/deadline-approaching-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-class-action-by-december-15-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/deadline-approaching-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-class-action-by-december-15-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODU2OCM3MzExMTc3IzIwODI5NjI=","datePublished":"2025-12-08T15:48:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/deadline-approaching-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-class-action-by-december-15-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/deadline-approaching-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-class-action-by-december-15-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/deadline-approaching-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-class-action-by-december-15-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODU2OCM3MzExMTc3IzIwODI5NjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODU2OCM3MzExMTc3IzIwODI5NjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/deadline-approaching-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-class-action-by-december-15-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"DEADLINE APPROACHING: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Inquire About a Securities Fraud Class Action by December 15, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/917419","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=917419"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/917419\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=917419"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=917419"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=917419"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}